Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer.
Fizazi
Karim
K
Institut Gustave Roussy, University of Paris XI, Villejuif, France, and Charité, Universitätsmedizin Berlin, Berlin, Germany. fizazi@igr.fr
Miller
Kurt
K
D017326:Clinical Trials, Phase III as Topic; D065130:Endothelin A Receptor Antagonists; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011759:Pyrrolidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D065130:Endothelin A Receptor Antagonists; D011759:Pyrrolidines; C511404:ZD4054